Daily Endocrinology Research Analysis
Two phase 3b randomized trials show that once-weekly semaglutide 7.2 mg delivers superior weight loss versus standard 2.4 mg (in obesity) and improves weight, waist circumference, and HbA1c versus placebo (in obesity with type 2 diabetes). Complementing therapeutic advances, a Nature Metabolism study in 8,391 multi-ethnic Asian participants develops plasma metabolite biomarker panels that objectively quantify diet and better predict cardiometabolic outcomes than self-reports.
Summary
Two phase 3b randomized trials show that once-weekly semaglutide 7.2 mg delivers superior weight loss versus standard 2.4 mg (in obesity) and improves weight, waist circumference, and HbA1c versus placebo (in obesity with type 2 diabetes). Complementing therapeutic advances, a Nature Metabolism study in 8,391 multi-ethnic Asian participants develops plasma metabolite biomarker panels that objectively quantify diet and better predict cardiometabolic outcomes than self-reports.
Research Themes
- Escalation of anti-obesity pharmacotherapy dosing
- Incretin-based therapy optimization in type 2 diabetes with obesity
- Objective diet biomarkers and precision nutrition
Selected Articles
1. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.
In a large, multicountry, phase 3b, double-blind trial (n=1407), once-weekly semaglutide 7.2 mg achieved greater bodyweight reduction than both 2.4 mg and placebo in adults with obesity, with a favorable risk–benefit profile. This supports dose escalation for individuals not achieving weight goals on 2.4 mg.
Impact: This is the first large randomized trial demonstrating superiority of semaglutide 7.2 mg over 2.4 mg for weight loss, potentially redefining dosing strategies in obesity care.
Clinical Implications: For patients not achieving sufficient weight loss on 2.4 mg, escalation to 7.2 mg may yield additional clinically meaningful weight reduction, with monitoring for known GI adverse effects and access considerations.
Key Findings
- Semaglutide 7.2 mg produced greater bodyweight reduction than 2.4 mg and placebo in adults with obesity.
- The trial was double-blind with active and placebo controls across 95 sites in 11 countries (n=1407).
- Risk–benefit profile remained favorable at the higher dose.
Methodological Strengths
- Phase 3b randomized, double-blind, active- and placebo-controlled design
- Large sample size and multicountry, multisite execution
Limitations
- Industry-funded trial may introduce sponsorship bias
- Long-term weight maintenance and safety beyond the study period are not detailed in the abstract
Future Directions: Head-to-head comparative effectiveness studies across anti-obesity agents and real-world implementation data on 7.2 mg tolerability, access, and maintenance are needed.
BACKGROUND: Once-weekly subcutaneous semaglutide 2·4 mg is approved for weight management in people with obesity and related complications; however, some individuals do not reach their therapeutic goals with this dose. We aimed to test the efficacy and safety of a higher dose of semaglutide (7·2 mg) in people with obesity. METHODS: STEP UP was a phase 3b, randomised, double-blind, placebo-controlled and active-controlled trial conducted across 95 hospitals, specialist clinics, and medical centres in 11 countries in adults with BMI 30 kg/m FINDINGS: Between Jan 1, 2023, and Nov 26, 2024, 1407 participants were randomly assigned to semaglutide 7·2 mg (n=1005), semaglutide 2·4 mg (n=201), or placebo (n=201). 1037 (73·7%) of 1407 participants were female, the mean age was 47 (SD 12) years, mean bodyweight was 113·0 (24·1) kg, and mean BMI was 39·9 (7·1) kg/m INTERPRETATION: Semaglutide 7·2 mg was superior to placebo and 2·4 mg for bodyweight reduction in adults with obesity, while retaining a favourable risk-benefit profile. FUNDING: Novo Nordisk. TRANSLATIONS: For the German and Greek translations of the abstract see Supplementary Materials section.
2. Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial.
In adults with obesity and type 2 diabetes (n=512), once-weekly semaglutide 7.2 mg was superior to placebo in reducing bodyweight, waist circumference, and HbA1c, in a double-blind, multicentre, phase 3b trial. These findings support dose escalation strategies when both weight and glycaemic targets are unmet.
Impact: Demonstrates that higher-dose semaglutide can simultaneously address weight and glycaemia in T2D with obesity, informing integrated, outcome-focused care.
Clinical Implications: For people with T2D and obesity not meeting goals, escalation to 7.2 mg may enhance weight loss and HbA1c reduction beyond lifestyle and standard-dose therapy, with standard monitoring for GLP-1RA adverse effects.
Key Findings
- Semaglutide 7.2 mg reduced bodyweight, waist circumference, and HbA1c more than placebo in adults with obesity and T2D.
- Randomized, double-blind, three-arm, parallel-group design across 68 sites (n=512).
- Provides evidence for dose escalation when 2.4 mg is insufficient in T2D with obesity.
Methodological Strengths
- Double-blind, multicentre, randomized phase 3b design
- Clinically relevant endpoints including anthropometrics and HbA1c
Limitations
- Comparative efficacy versus 2.4 mg is not fully specified in the abstract
- Longer-term maintenance and cardiovascular outcomes were not addressed
Future Directions: Evaluate long-term maintenance, cardiovascular outcomes, and comparative effectiveness versus other anti-obesity and glucose-lowering agents at higher doses.
BACKGROUND: Semaglutide 2·4 mg is approved for weight management in adults with obesity or overweight in the presence of at least one obesity-related complication; however, many people with obesity and type 2 diabetes do not reach their bodyweight reduction goals with this dose. We aimed to investigate the efficacy and safety of a new 7·2 mg maintenance dose of once-weekly subcutaneous semaglutide in people with obesity and type 2 diabetes. METHODS: STEP UP T2D was a randomised, phase 3b, double-blind controlled, three-arm, parallel-group trial conducted at 68 hospitals, specialist clinics, and medical centres in Bulgaria, Canada, Hungary, Poland, Portugal, Slovakia, South Africa, and the USA. Adults aged 18 years or older (BMI ≥30·0 kg/m FINDINGS: Between Jan 4 and May 4, 2023, 512 participants were randomly assigned to receive semaglutide 7·2 mg (n=307), semaglutide 2·4 mg (n=103), or placebo (n=102). 265 (51·8%) of 512 participants were female, the mean age was 56 (SD 10) years, mean bodyweight was 110·1 (22·9) kg, mean BMI was 38·6 (7·1) kg/m INTERPRETATION: Among people with obesity and type 2 diabetes, semaglutide 7·2 mg was superior to placebo in reducing bodyweight, waist circumference, and HbA FUNDING: Novo Nordisk. TRANSLATIONS: For the Bulgarian, Hungarian and Polish translations of the abstract see Supplementary Materials section.
3. Metabolic variation reflects dietary exposure in a multi-ethnic Asian population.
In 8,391 multi-ethnic Asian adults, plasma metabolomics and machine learning yielded multi-biomarker panels that objectively quantify dietary exposure and outperform self-reported diet in predicting insulin resistance, diabetes, BMI, carotid intima-media thickness, and hypertension. Diet–metabolite associations were reproducible over time, enabling objective monitoring for precision nutrition.
Impact: Provides scalable, objective diet biomarkers in a large, underrepresented population, linking exposure to clinically relevant cardiometabolic outcomes.
Clinical Implications: Objective diet biomarkers could augment dietary assessment in clinics and trials, improving risk stratification and evaluation of nutrition interventions beyond self-reports.
Key Findings
- Assessed 1,055 plasma metabolites and 169 foods/beverages in 8,391 multi-ethnic Asian individuals.
- Machine learning-derived multi-biomarker panels objectively quantified dietary exposure and outperformed self-reports in predicting insulin resistance, diabetes, BMI, carotid IMT, and hypertension.
- Diet–metabolite associations were reproducible over time, supporting longitudinal utility.
Methodological Strengths
- Large, multi-ethnic cohort with comprehensive plasma metabolomics
- Rigorous machine learning model development with temporal reproducibility assessment
Limitations
- Predominantly cross-sectional associations limit causal inference
- Generalizability to non-Asian populations requires validation
Future Directions: Prospective validation of biomarker panels for intervention monitoring, integration into clinical risk models, and extension to diverse global populations.
Understanding how diet shapes metabolism across diverse populations is essential to improving nutrition and health. Biomarkers reflecting diet are explored largely in European and American populations, but the food metabolome is highly complex and varies across region and culture. We assessed 1,055 plasma metabolites and 169 foods/beverages in 8,391 multi-ethnic Asian individuals and carried out diet-metabolite association analyses. Using machine learning, we developed multi-biomarker panels and composite scores for key foods, beverages and overall diet quality. Here we show these biomarker panels can be used to objectively assess dietary intakes in the Asian multi-ethnic population and can explain variances in intake prediction models better than single biomarkers. The identified diet-metabolite relationships are reproducible over time and improve prediction of clinical outcomes (insulin resistance, diabetes, body mass index, carotid intima-media thickness and hypertension), compared to self-reports. Our findings show insights into multi-ethnic diet-related metabolic variations and an opportunity to link exposure to population health outcomes.